An open-label, multiple dose, randomized, two-way crossover study to evaluate the effects of BGG492 on the pharmacokinetics and pharmacodynamics of a monophasic oral contraceptive in healthy female volunteers

Completed

• Conditions: Epilepsie; Epilepsia; falling disease

• Registration Number: NL-OMON34415
• Lead Sponsor: ovartis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 24

Inclusion Criteria

Young females, 18-40 years, BMI 18-29 kg/m2, non-smokers, OC-user

Exclusion Criteria

Clinical significant abnormalities during screening and baseline

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics of EES and LVG on dag 14</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics of EES and LVG on dag 21<br /><br>PK profile of BGG492<br /><br>Pharmacodynamics<br /><br>Safety</p><br>